Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE)

    Summary
    EudraCT number
    2020-006003-42
    Trial protocol
    DK  
    Global end of trial date
    31 Dec 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    28 Feb 2025
    First version publication date
    28 Feb 2025
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    ENFORCE
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04760132
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    CHIP - Rigshospitalet - University of Copenhagen
    Sponsor organisation address
    Blegdamsvej 9, Section 2100, COPENHAGEN, Denmark, 2100
    Public contact
    Jens Lundgren, CHIP - Rigshospitalet, University of Copenhagen, 45 3545 5757, jens.lundgren@regionh.dk
    Scientific contact
    Jens Lundgren, CHIP - Rigshospitalet, University of Copenhagen, 45 3545 5757, jens.lundgren@regionh.dk
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    31 Dec 2023
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    31 Dec 2023
    Global end of trial reached?
    Yes
    Global end of trial date
    31 Dec 2023
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    The primary objective of the study is to assess effectiveness of citizens being vaccinated with one of SARS-CoV2 vaccines the government has purchased, and the Danish Medicines Agency has approved for use in Denmark. The study will compare and predict the durability of the minimal protective titre afforded by each of the vaccines against COVID-19 through conducting comprehensive high-throughput SARS-CoV-2 antibody analyses and in-depth characterization of the vaccine-induced cellular immune response.
    Protection of trial subjects
    Informed Consent is obtained from the participant before any trial-related procedures were conducted.
    Background therapy
    As the study was observing the effect and roll-out of a vaccination programme in the middle of an ongoing epidemic, there were some changes in the study due to changes in the political environment. 1. The intended 4 arms were reduced to 3, as one of the vaccines was stopped by the government due to high risk of unintended and fatal side-effects. 2. ENFORCE set out to monitor the immunological response to the standard recommended COVID-19 vaccine regimens at the time of inception over a two-year period (i.e., two doses). However, the need of additional doses (3 or 4) to further boost/preserve immunity was clarified in the second half 2021 and ENFORCE was approved to observe the evolving use of vaccines during a 5-year follow-up of the cohort. 3. It was also decided, that ENFORCE should continue to assess the impact new vaccine technologies, that would be licensed and used in the cohort as part of the national vaccine program, as well as additional doses of existing vaccines. As an observation study it will not interfere with the participants choice of receiving such doses/types of vaccines.
    Evidence for comparator
    -
    Actual start date of recruitment
    08 Feb 2021
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Denmark: 6941
    Worldwide total number of subjects
    6941
    EEA total number of subjects
    6941
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    3733
    From 65 to 84 years
    3200
    85 years and over
    8

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study population consisted of consecutive consenting persons who were invited to be vaccinated at 20- 50 participating units throughout Denmark. A targeted effort was made to enrol a high proportion of participants who was considered at ‘high-risk’ of COVID-19 (as defined by SST in the national vaccination plan).

    Pre-assignment
    Screening details
    Subjects to be vaccinated with one of the COVID-19 vaccines given as part of the Danish COVID-19 Vaccine Program.

    Period 1
    Period 1 title
    Entire Trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Vaccine COMIRNATY
    Arm description
    Comirnaty is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 16 years and older. Comirnaty contains a molecule called messenger RNA (mRNA) with instructions for producing a protein from SARS-CoV-2, the virus that causes COVID-19. Comirnaty does not contain the virus itself and cannot cause COVID-19. The active substance is a single-stranded, 5´-capped messenger RNA produced using a cell-free in vitro transcription from corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2
    Arm type
    Strategy

    Investigational medicinal product name
    Vaccine Comirnaty
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    The vaccine is not IMP in the trial, but used according to the approved Summary of Product Characteristics - and is given as part of the Danish COVID-19 Vaccine Program.

    Arm title
    Vaccine Moderna
    Arm description
    COVID-19 Vaccine Moderna is a vaccine used to prevent COVID-19 caused by SARS-CoV-2. It is given to adults aged 18 years and older. The active substance in COVID-19 Vaccine Moderna is mRNA encoding the SARS-CoV-2 Spike protein. The mRNA is embedded in SM-102 lipid nanoparticles. As COVID-19 Vaccine Moderna does not contain the virus, it cannot cause COVID-19.
    Arm type
    Strategy

    Investigational medicinal product name
    Vaccine Moderna
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    The vaccine is not IMP in the trial, but used according to the approved Summary of Product Characteristics - and is given as part of the Danish COVID-19 Vaccine Program.

    Arm title
    Vaccine AstraZeneca
    Arm description
    COVID-19 Vaccine AstraZeneca is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years and older. One dose (0.5 ml.) contains Chimpanzee Adenovirus encoding the SARS-CoV-2 Spike glycoprotein (ChAdOx1-s), not less than 2.5 x 108 infectious units (Inf.U) COVID-19 Vaccine AstraZeneca is a monovalent vaccine composed of a single recombinant, replication-deficient chimpanzee adenovirus (ChAdOx1) vector encoding the S glycoprotein of SARS-CoV-2.
    Arm type
    Strategy

    Investigational medicinal product name
    Vaccine AstraZeneca
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    The vaccine is not IMP in the trial, but used according to the approved Summary of Product Characteristics - and is given as part of the Danish COVID-19 Vaccine Program.

    Number of subjects in period 1
    Vaccine COMIRNATY Vaccine Moderna Vaccine AstraZeneca
    Started
    3823
    2620
    498
    Completed
    3823
    2620
    498

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Entire Trial (overall period)
    Reporting group description
    -

    Reporting group values
    Entire Trial (overall period) Total
    Number of subjects
    6941 6941
    Age categorical
    Units: Subjects
        In utero
    0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days-23 months)
    0 0
        Children (2-11 years)
    0 0
        Adolescents (12-17 years)
    0 0
        Adults (18-64 years)
    3733 3733
        From 65-84 years
    3200 3200
        85 years and over
    8 8
    Gender categorical
    Units: Subjects
        Female
    3928 3928
        Male
    3013 3013

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Vaccine COMIRNATY
    Reporting group description
    Comirnaty is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 16 years and older. Comirnaty contains a molecule called messenger RNA (mRNA) with instructions for producing a protein from SARS-CoV-2, the virus that causes COVID-19. Comirnaty does not contain the virus itself and cannot cause COVID-19. The active substance is a single-stranded, 5´-capped messenger RNA produced using a cell-free in vitro transcription from corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2

    Reporting group title
    Vaccine Moderna
    Reporting group description
    COVID-19 Vaccine Moderna is a vaccine used to prevent COVID-19 caused by SARS-CoV-2. It is given to adults aged 18 years and older. The active substance in COVID-19 Vaccine Moderna is mRNA encoding the SARS-CoV-2 Spike protein. The mRNA is embedded in SM-102 lipid nanoparticles. As COVID-19 Vaccine Moderna does not contain the virus, it cannot cause COVID-19.

    Reporting group title
    Vaccine AstraZeneca
    Reporting group description
    COVID-19 Vaccine AstraZeneca is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years and older. One dose (0.5 ml.) contains Chimpanzee Adenovirus encoding the SARS-CoV-2 Spike glycoprotein (ChAdOx1-s), not less than 2.5 x 108 infectious units (Inf.U) COVID-19 Vaccine AstraZeneca is a monovalent vaccine composed of a single recombinant, replication-deficient chimpanzee adenovirus (ChAdOx1) vector encoding the S glycoprotein of SARS-CoV-2.

    Primary: Antibody Level

    Close Top of page
    End point title
    Antibody Level
    End point description
    Primary Outcome: Minimal protective neutralising antibody titre (MPNAT) i.e. the minimum level of neutralising antibodies sufficient to protect the person from becoming infected. MPNAT will be measured via profiling of antibodies against SARS-CoV-2 Spike epitopes performed at each visit until month 60. We will use two different large-scale methods. 1. ELISA detection of total serum Ig to the Receptor Binding Domain (Wantai), this specific method will be stopped after January 2023 as the positive rate has reached 99%. 2. A multiantigen serological test including both the N-terminal Domain (NTD), The Receptor Binding Domain (RBD), the complete Spike (S) protein and the Nucleocapsid (NC) protein as antigens (from Mesoscale). Additionally, an ACE2 competition assay will be used to score the receptor blocking potential of antibodies raised by vaccination (Mesoscale).
    End point type
    Primary
    End point timeframe
    Antibody level will be measured via profiling of antibodies against SARS-CoV-2 Spike epitopes performed at each visit until month 24.
    End point values
    Vaccine COMIRNATY Vaccine Moderna Vaccine AstraZeneca
    Number of subjects analysed
    3749
    2541
    481
    Units: Number of participants
        SSI Antibody data 0-14 days before 3rd dose
    1395
    1165
    160
        Wantai result prior to booster - Negative
    43
    1
    0
        Wantai result prior to booster - Positive
    1352
    1163
    160
        Wantai result prior to booster - Inconclusive
    0
    1
    0
        SSI Antibody data 28 days after 3rd dose
    2269
    1883
    269
        Wantai result after booster - Negative
    40
    7
    0
        Wantai result after booster - Positive
    2227
    1875
    269
        Wantai result after booster - Inconclusive
    2
    1
    0
    Statistical analysis title
    Total spike IgG Geometric Mean
    Statistical analysis description
    For antibody response to each of the vaccines and subsequent vaccine dose, we reported the geometric means together with 95% confidence intervals (2-sided).
    Comparison groups
    Vaccine COMIRNATY v Vaccine Moderna v Vaccine AstraZeneca
    Number of subjects included in analysis
    6771
    Analysis specification
    Pre-specified
    Analysis type
    other [1]
    Method
    Parameter type
    Geometric mean
    Point estimate
    473602
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    467043
         upper limit
    480252
    Notes
    [1] - There was no formal statistical comparison as the aim of the study was not to compare the response to the different vaccines. The outcome at the 2 yearsstudy visit was presented stratified by the number of doses an individual had received rather than by vaccine type as participants received different vaccine combinations. The geometric mean antibody levels at each study visit were plotted graphically together with the 95% confidence intervals.

    Secondary: Breakthrough infections

    Close Top of page
    End point title
    Breakthrough infections
    End point description
    Breakthrough infection was defined as a positive SARS-CoV-2 PCR test result reported in the KIDS dataset after the date of first vaccination. The timing of the infection was based on the date of first positive test. The number of participants experiencing a positive PCR test following their first vaccination 4473 participants remaining in the study. Overall, half of the cohort had tested positive for SARS-CoV-2 at least once since their first vaccination and prior to the end of the study (31st December 2023). A higher proportion of younger individuals (< 55 years) had experienced a breakthrough infection defined by a positive PCR test compared to those aged ≥65 years.
    End point type
    Secondary
    End point timeframe
    Breakthrough infections throughout the 24 month follow-up period
    End point values
    Vaccine COMIRNATY Vaccine Moderna Vaccine AstraZeneca
    Number of subjects analysed
    3823
    2620
    498
    Units: Number of participants
        Ever tested for SARS-CoV-2 via KIDS
    3599
    2537
    496
        Participants testing positive for SARS-CoV-2
    1594
    1195
    317
        Days from first vaccine dose to positive test
    320
    268
    340
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Timeframe 3 months after vaccination.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    24.1
    Reporting groups
    Reporting group title
    Vaccine COMIRNATY
    Reporting group description
    Number of persons with at least one Adverse Event reported

    Reporting group title
    Vaccine Moderna
    Reporting group description
    Number of persons with at least one Adverse Event reported

    Reporting group title
    Vaccine AstraZeneca
    Reporting group description
    Number of persons with at least one Adverse Event reported

    Serious adverse events
    Vaccine COMIRNATY Vaccine Moderna Vaccine AstraZeneca
    Total subjects affected by serious adverse events
         subjects affected / exposed
    112 / 3824 (2.93%)
    32 / 2620 (1.22%)
    6 / 499 (1.20%)
         number of deaths (all causes)
    41
    12
    0
         number of deaths resulting from adverse events
    0
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Benign neoplasm of testis
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Bladder cancer
         subjects affected / exposed
    2 / 3824 (0.05%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Breast cancer
         subjects affected / exposed
    1 / 3824 (0.03%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Chronic lymphocytic leukaemia
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Colon cancer
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Colon cancer metastatic
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Diffuse large B-cell lymphoma
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastric cancer
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Intraductal proliferative breast lesion
         subjects affected / exposed
    0 / 3824 (0.00%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Lung neoplasm malignant
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Malignant neoplasm progression
         subjects affected / exposed
    6 / 3824 (0.16%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 6
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Metastases to liver
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Tongue neoplasm malignant stage unspecified
         subjects affected / exposed
    0 / 3824 (0.00%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Aortic aneurysm
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Aortic dissection
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Deep vein thrombosis
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Orthostatic hypertension
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Surgical and medical procedures
    Cardiac resynchronisation therapy
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Adverse drug reaction
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Chest pain
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hernia
         subjects affected / exposed
    0 / 3824 (0.00%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Multiple organ dysfunction syndrome
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed
    5 / 3824 (0.13%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Withdrawal syndrome
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Immune system disorders
    Kidney transplant rejection
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Acute allograft nephropathy
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Anaphylactic reaction
         subjects affected / exposed
    3 / 3824 (0.08%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Graft versus host disease
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hypersensitivity
         subjects affected / exposed
    0 / 3824 (0.00%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Liver transplant rejection
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Solid organ transplant rejection
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Acute respiratory distress syndrome
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Chronic obstructive pulmonary disease
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Epistaxis
         subjects affected / exposed
    2 / 3824 (0.05%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    2 / 3824 (0.05%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Completed suicide
         subjects affected / exposed
    0 / 3824 (0.00%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Suicidal ideation
         subjects affected / exposed
    2 / 3824 (0.05%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    2 / 3824 (0.05%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Fracture
         subjects affected / exposed
    1 / 3824 (0.03%)
    1 / 2620 (0.04%)
    1 / 499 (0.20%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Post procedural complication
         subjects affected / exposed
    0 / 3824 (0.00%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Post procedural haemorrhage
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Road traffic accident
         subjects affected / exposed
    0 / 3824 (0.00%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Acute myocardial infarction
         subjects affected / exposed
    4 / 3824 (0.10%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Angina pectoris
         subjects affected / exposed
    1 / 3824 (0.03%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Arrhythmia
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Atrial fibrillation
         subjects affected / exposed
    4 / 3824 (0.10%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    1 / 4
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Atrial flutter
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Atrioventricular block complete
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cardiac failure congestive
         subjects affected / exposed
    3 / 3824 (0.08%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Coronary artery disease
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Extrasystoles
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Ventricular tachyarrhythmia
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Cerebellar stroke
         subjects affected / exposed
    0 / 3824 (0.00%)
    0 / 2620 (0.00%)
    1 / 499 (0.20%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cerebral haemorrhage
         subjects affected / exposed
    0 / 3824 (0.00%)
    0 / 2620 (0.00%)
    1 / 499 (0.20%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cerebrovascular accident
         subjects affected / exposed
    3 / 3824 (0.08%)
    2 / 2620 (0.08%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Haemorrhage intracranial
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Headache
         subjects affected / exposed
    0 / 3824 (0.00%)
    0 / 2620 (0.00%)
    1 / 499 (0.20%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Multiple sclerosis
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Normal pressure hydrocephalus
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Presyncope
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Tension headache
         subjects affected / exposed
    0 / 3824 (0.00%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Transient ischaemic attack
         subjects affected / exposed
    4 / 3824 (0.10%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Febrile neutropenia
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Lymphadenopathy
         subjects affected / exposed
    0 / 3824 (0.00%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    Cerumen impaction
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Vertigo positional
         subjects affected / exposed
    0 / 3824 (0.00%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Eye disorders
    Retinal vein thrombosis
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    0 / 3824 (0.00%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Crohn's disease
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    2 / 3824 (0.05%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Dysphagia
         subjects affected / exposed
    0 / 3824 (0.00%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastritis
         subjects affected / exposed
    0 / 3824 (0.00%)
    0 / 2620 (0.00%)
    1 / 499 (0.20%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    2 / 3824 (0.05%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastrooesophageal reflux disease
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Ileus
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Intestinal ischaemia
         subjects affected / exposed
    0 / 3824 (0.00%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Large intestinal haemorrhage
         subjects affected / exposed
    0 / 3824 (0.00%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Mechanical ileus
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Autoimmune hepatitis
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cholangitis
         subjects affected / exposed
    2 / 3824 (0.05%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cholangitis acute
         subjects affected / exposed
    4 / 3824 (0.10%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cholecystitis acute
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cholelithiasis
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Jaundice cholestatic
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Portal vein thrombosis
         subjects affected / exposed
    2 / 3824 (0.05%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Pyoderma gangrenosum
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Urticaria
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Skin ulcer
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Nephrolithiasis
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Haemarthrosis
         subjects affected / exposed
    0 / 3824 (0.00%)
    0 / 2620 (0.00%)
    1 / 499 (0.20%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Orchitis
         subjects affected / exposed
    0 / 3824 (0.00%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Anal abscess
         subjects affected / exposed
    1 / 3824 (0.03%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Appendicitis
         subjects affected / exposed
    2 / 3824 (0.05%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    COVID-19
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    3 / 3824 (0.08%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Clostridium difficile infection
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cystitis escherichia
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Diverticulitis
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis salmonella
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Herpes zoster
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Peritonitis bacterial
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    4 / 3824 (0.10%)
    3 / 2620 (0.11%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Post procedural infection
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Psoas abscess
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pyelonephritis
         subjects affected / exposed
    1 / 3824 (0.03%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Respiratory tract infection
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    2 / 3824 (0.05%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    3 / 3824 (0.08%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Urosepsis
         subjects affected / exposed
    0 / 3824 (0.00%)
    2 / 2620 (0.08%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Vestibular neuronitis
         subjects affected / exposed
    1 / 3824 (0.03%)
    0 / 2620 (0.00%)
    0 / 499 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    Vaccine COMIRNATY Vaccine Moderna Vaccine AstraZeneca
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    487 / 3824 (12.74%)
    395 / 2620 (15.08%)
    94 / 499 (18.84%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Neoplasm
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    1 / 3824 (0.03%)
    2 / 2620 (0.08%)
    0 / 499 (0.00%)
         occurrences all number
    1
    2
    0
    Vascular disorders
    Vascular disorder
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    15 / 3824 (0.39%)
    11 / 2620 (0.42%)
    4 / 499 (0.80%)
         occurrences all number
    15
    11
    4
    Surgical and medical procedures
    Surgical procedure
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    15 / 3824 (0.39%)
    6 / 2620 (0.23%)
    1 / 499 (0.20%)
         occurrences all number
    15
    6
    1
    Pregnancy, puerperium and perinatal conditions
    Abortion spontaneous
         subjects affected / exposed
    0 / 3824 (0.00%)
    0 / 2620 (0.00%)
    1 / 499 (0.20%)
         occurrences all number
    0
    0
    1
    General disorders and administration site conditions
    Administration site discomfort
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    127 / 3824 (3.32%)
    173 / 2620 (6.60%)
    44 / 499 (8.82%)
         occurrences all number
    127
    173
    44
    Immune system disorders
    Immune system disorder
         subjects affected / exposed
    4 / 3824 (0.10%)
    6 / 2620 (0.23%)
    1 / 499 (0.20%)
         occurrences all number
    4
    6
    1
    Reproductive system and breast disorders
    Reproductive system disorder
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    5 / 3824 (0.13%)
    1 / 2620 (0.04%)
    3 / 499 (0.60%)
         occurrences all number
    5
    1
    3
    Respiratory, thoracic and mediastinal disorders
    Respiratory disorder
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    46 / 3824 (1.20%)
    27 / 2620 (1.03%)
    7 / 499 (1.40%)
         occurrences all number
    46
    27
    7
    Psychiatric disorders
    Psychiatric disorder
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    8 / 3824 (0.21%)
    11 / 2620 (0.42%)
    5 / 499 (1.00%)
         occurrences all number
    8
    11
    5
    Investigations
    Investigation
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    6 / 3824 (0.16%)
    5 / 2620 (0.19%)
    1 / 499 (0.20%)
         occurrences all number
    6
    5
    1
    Injury, poisoning and procedural complications
    Complications
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    38 / 3824 (0.99%)
    21 / 2620 (0.80%)
    7 / 499 (1.40%)
         occurrences all number
    38
    21
    7
    Cardiac disorders
    Cardiac disorder
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    17 / 3824 (0.44%)
    8 / 2620 (0.31%)
    1 / 499 (0.20%)
         occurrences all number
    17
    8
    1
    Nervous system disorders
    Nervous system disorder
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    66 / 3824 (1.73%)
    45 / 2620 (1.72%)
    18 / 499 (3.61%)
         occurrences all number
    66
    45
    18
    Blood and lymphatic system disorders
    Blood disorder
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    5 / 3824 (0.13%)
    1 / 2620 (0.04%)
    0 / 499 (0.00%)
         occurrences all number
    5
    1
    0
    Ear and labyrinth disorders
    Ear disorder
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    3 / 3824 (0.08%)
    2 / 2620 (0.08%)
    1 / 499 (0.20%)
         occurrences all number
    3
    2
    1
    Eye disorders
    Eye disorder
    Additional description: Due to the high number of participants participating in the study the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    5 / 3824 (0.13%)
    7 / 2620 (0.27%)
    0 / 499 (0.00%)
         occurrences all number
    5
    7
    0
    Gastrointestinal disorders
    Gastrointestinal disorder
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    52 / 3824 (1.36%)
    27 / 2620 (1.03%)
    3 / 499 (0.60%)
         occurrences all number
    52
    27
    3
    Hepatobiliary disorders
    Hepatobiliary disease
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    2 / 3824 (0.05%)
    4 / 2620 (0.15%)
    0 / 499 (0.00%)
         occurrences all number
    2
    4
    0
    Skin and subcutaneous tissue disorders
    Skin disorder
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    12 / 3824 (0.31%)
    18 / 2620 (0.69%)
    7 / 499 (1.40%)
         occurrences all number
    12
    18
    7
    Renal and urinary disorders
    Renal disorder
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    6 / 3824 (0.16%)
    6 / 2620 (0.23%)
    0 / 499 (0.00%)
         occurrences all number
    6
    6
    0
    Endocrine disorders
    Endocrine disorder
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    4 / 3824 (0.10%)
    2 / 2620 (0.08%)
    1 / 499 (0.20%)
         occurrences all number
    4
    2
    1
    Musculoskeletal and connective tissue disorders
    Musculoskeletal disorder
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    82 / 3824 (2.14%)
    54 / 2620 (2.06%)
    10 / 499 (2.00%)
         occurrences all number
    82
    54
    10
    Infections and infestations
    Infection
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    78 / 3824 (2.04%)
    81 / 2620 (3.09%)
    13 / 499 (2.61%)
         occurrences all number
    78
    81
    13
    Metabolism and nutrition disorders
    Metabolic disorder
    Additional description: Due to in general the high number of participants in the study, the numbers for this system organ class consists of several different preferred terms. A detailed report is available upon request.
         subjects affected / exposed
    17 / 3824 (0.44%)
    7 / 2620 (0.27%)
    1 / 499 (0.20%)
         occurrences all number
    17
    7
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 11:46:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA